PolynovoCALZF 75 14-Day RSI is 25.92 as of Jul. 13, 2026. GuruFocus rates CALZF with a GF Score™ of 75/100 and a GF Value™ of $2.22 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 868 Medical Devices & Instruments companies, Polynovo ranks worse than 68.78% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-13), Polynovo's 14-Day RSI is 25.92.
The industry rank for Polynovo's 14-Day RSI or its related term are showing as below:
CALZF's 14-Day RSI is ranked worse than 68.78% of 868
companies
in the Medical Devices & Instruments industry
Industry Median: 47.695
vs CALZF: 25.92
Polynovo (OTCPK:CALZF) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Polynovo 14-Day RSI Related Terms
CALZF vs ABT, SYK, MDT: 14-Day RSI Comparison
For the Medical Devices subindustry, Polynovo's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polynovo 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Polynovo's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Polynovo's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Polynovo (CALZF) has a 14-Day RSI of 25.92 as of Jul. 13, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Polynovo and its competitors. According to the industry distribution chart, Polynovo ranks #597 out of 868 companies in the Medical Devices & Instruments industry, placing it in the top 68.8%.
Is Polynovo's 14-Day RSI too high?
Polynovo's current 14-Day RSI is 25.92. The Medical Devices & Instruments industry median 14-Day RSI is 47.70. Polynovo's value of 25.92 is 45.7% below this industry median. Based on the distribution chart, Polynovo ranks #597 out of 868 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Polynovo has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Polynovo's 14-Day RSI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Polynovo ranks #597 out of 868 companies for 14-Day RSI. This places Polynovo in the lower half of its industry. The industry median 14-Day RSI is 47.70. Polynovo's value of 25.92 is 45.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 47.70, based on 868 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Polynovo's current 14-Day RSI of 25.92 is 45.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Polynovo and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 47.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polynovo's current 14-Day RSI is 25.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polynovo stock overvalued right now?
Based on GuruFocus' analysis, Polynovo (CALZF) is currently considered Significantly Undervalued. The stock's GF Value™ is $2.22, compared to a current price of $0.62 — trading 72.1% below its estimated fair value. The current 14-Day RSI is 25.92 and 45.7% below the Medical Devices & Instruments industry median of 47.70. Polynovo's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Polynovo (CALZF), the current 14-Day RSI is 25.92 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polynovo (CALZF) Overvalued in 2026?
Based on GuruFocus' analysis, Polynovo stock appears to be undervalued.
The current stock price of $0.62 is trading 72.1% below its estimated GF Value™ of $2.22.
GuruFocus considers Polynovo to be Significantly Undervalued.
Key valuation signals for CALZF:
14-Day RSI: 25.92
GF Value™: $2.22 vs. price of $0.62 (72.1% below fair value)
Industry Position: 45.7% below the Medical Devices & Instruments median (#597 of 868)
No single metric tells the full story. See the CALZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita's RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.
75GF Score
Get the complete analysis for CALZF
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CALZF has been successfully added to your 